S&P 500   3,242.82 (-2.84%)
DOW   28,121.91 (-3.00%)
QQQ   222.92 (-3.19%)
AAPL   301.40 (-3.72%)
FB   200.50 (-4.61%)
MSFT   172.94 (-3.16%)
GOOGL   1,420.18 (-4.27%)
AMZN   2,010.73 (-4.07%)
CGC   20.33 (-7.09%)
NVDA   276.45 (-5.99%)
BABA   205.73 (-3.23%)
TSLA   840.37 (-6.73%)
AMD   49.89 (-6.36%)
ACB   1.55 (-7.19%)
F   7.63 (-3.30%)
NFLX   370.78 (-2.44%)
BAC   32.81 (-4.51%)
S&P 500   3,242.82 (-2.84%)
DOW   28,121.91 (-3.00%)
QQQ   222.92 (-3.19%)
AAPL   301.40 (-3.72%)
FB   200.50 (-4.61%)
MSFT   172.94 (-3.16%)
GOOGL   1,420.18 (-4.27%)
AMZN   2,010.73 (-4.07%)
CGC   20.33 (-7.09%)
NVDA   276.45 (-5.99%)
BABA   205.73 (-3.23%)
TSLA   840.37 (-6.73%)
AMD   49.89 (-6.36%)
ACB   1.55 (-7.19%)
F   7.63 (-3.30%)
NFLX   370.78 (-2.44%)
BAC   32.81 (-4.51%)
S&P 500   3,242.82 (-2.84%)
DOW   28,121.91 (-3.00%)
QQQ   222.92 (-3.19%)
AAPL   301.40 (-3.72%)
FB   200.50 (-4.61%)
MSFT   172.94 (-3.16%)
GOOGL   1,420.18 (-4.27%)
AMZN   2,010.73 (-4.07%)
CGC   20.33 (-7.09%)
NVDA   276.45 (-5.99%)
BABA   205.73 (-3.23%)
TSLA   840.37 (-6.73%)
AMD   49.89 (-6.36%)
ACB   1.55 (-7.19%)
F   7.63 (-3.30%)
NFLX   370.78 (-2.44%)
BAC   32.81 (-4.51%)
S&P 500   3,242.82 (-2.84%)
DOW   28,121.91 (-3.00%)
QQQ   222.92 (-3.19%)
AAPL   301.40 (-3.72%)
FB   200.50 (-4.61%)
MSFT   172.94 (-3.16%)
GOOGL   1,420.18 (-4.27%)
AMZN   2,010.73 (-4.07%)
CGC   20.33 (-7.09%)
NVDA   276.45 (-5.99%)
BABA   205.73 (-3.23%)
TSLA   840.37 (-6.73%)
AMD   49.89 (-6.36%)
ACB   1.55 (-7.19%)
F   7.63 (-3.30%)
NFLX   370.78 (-2.44%)
BAC   32.81 (-4.51%)
Log in

NYSE:CTLT - Catalent Stock Price, Forecast & News

$56.09
-2.89 (-4.90 %)
(As of 02/24/2020 03:45 PM ET)
Today's Range
$55.34
Now: $56.09
$57.86
50-Day Range
$55.93
MA: $59.68
$62.95
52-Week Range
$39.09
Now: $56.09
$68.78
Volume28,828 shs
Average Volume1.30 million shs
Market Capitalization$8.21 billion
P/E Ratio66.77
Dividend YieldN/A
Beta1.69
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone732-537-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.52 billion
Cash Flow$3.15 per share
Book Value$11.54 per share

Profitability

Net Income$137.40 million

Miscellaneous

Employees12,300
Market Cap$8.21 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.


Catalent (NYSE:CTLT) Frequently Asked Questions

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

How were Catalent's earnings last quarter?

Catalent Inc (NYSE:CTLT) announced its earnings results on Monday, February, 3rd. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.06. The company had revenue of $721.40 million for the quarter, compared to analyst estimates of $700.81 million. Catalent had a return on equity of 15.21% and a net margin of 5.44%. The firm's quarterly revenue was up 15.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.45 earnings per share. View Catalent's Earnings History.

When is Catalent's next earnings date?

Catalent is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Catalent.

What guidance has Catalent issued on next quarter's earnings?

Catalent updated its FY 2020 Pre-Market earnings guidance on Monday, February, 3rd. The company provided earnings per share (EPS) guidance of 1.92-2.06 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.97. The company issued revenue guidance of $2.87-2.95 billion, compared to the consensus revenue estimate of $2.85 billion.

What price target have analysts set for CTLT?

6 analysts have issued 12 month price targets for Catalent's shares. Their forecasts range from $49.00 to $75.00. On average, they expect Catalent's stock price to reach $64.00 in the next year. This suggests a possible upside of 14.1% from the stock's current price. View Analyst Price Targets for Catalent.

What is the consensus analysts' recommendation for Catalent?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.

Has Catalent been receiving favorable news coverage?

News headlines about CTLT stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Catalent earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Catalent.

Who are some of Catalent's key competitors?

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Alibaba Group (BABA), AbbVie (ABBV), Energy Transfer LP Unit (ET), Thermo Fisher Scientific (TMO), Abbott Laboratories (ABT), CVS Health (CVS), Pfizer (PFE), Verizon Communications (VZ), NVIDIA (NVDA) and AT&T (T).

Who are Catalent's key executives?

Catalent's management team includes the folowing people:
  • Mr. John R. Chiminski, Chairman & CEO (Age 55)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)
  • Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53)
  • Mr. Alessandro Maselli, Pres & COO (Age 47)

Who are Catalent's major shareholders?

Catalent's stock is owned by a number of of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (11.28%), Champlain Investment Partners LLC (3.31%), Franklin Resources Inc. (2.48%), State Street Corp (2.39%), Earnest Partners LLC (1.85%) and FMR LLC (1.69%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Ricardo Pravda, Steven L Fasman and William Downie. View Institutional Ownership Trends for Catalent.

Which major investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., FMR LLC, Janus Henderson Group PLC, CWM LLC, GW&K Investment Management LLC, State of Tennessee Treasury Department, Loomis Sayles & Co. L P and UBS Asset Management Americas Inc.. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto, Michael J Grippo, Ricardo Pravda and Steven L Fasman. View Insider Buying and Selling for Catalent.

Which major investors are buying Catalent stock?

CTLT stock was acquired by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Westfield Capital Management Co. LP, Artisan Partners Limited Partnership, Schroder Investment Management Group, Bank of America Corp DE, Earnest Partners LLC, First Trust Advisors LP and Madison Asset Management LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch and Peter L Buzy. View Insider Buying and Selling for Catalent.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $56.09.

How big of a company is Catalent?

Catalent has a market capitalization of $8.21 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe.View Additional Information About Catalent.

What is Catalent's official website?

The official website for Catalent is http://www.catalent.com/.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]


MarketBeat Community Rating for Catalent (NYSE CTLT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  576 (Vote Outperform)
Underperform Votes:  657 (Vote Underperform)
Total Votes:  1,233
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel